This week, the world lost a champion. On June 3, 2019, Kim Fredrickson, a stoic and heroic inspiration to so many people living with pulmonary fibrosis (PF), died after nearly four months in the intensive care unit at UCSF Medical Center, where she was awaiting a life-saving…
Plans for a Phase 2 clinical trial of brilaroxazine, the lead candidate by Reviva Pharmaceuticals to treat idiopathic pulmonary fibrosis (IPF), were the focus of a recent and successful meeting between company officials and the U.S. Food and Drug Administration (FDA), Reviva announced. During this pre-Investigational New Drug (IND) Application meeting, the regulatory…
The Pulmonary Fibrosis Foundations (PFF)’ Patient Registry is providing valuable data to support pulmonary fibrosis research, as evidenced by multiple presentations at the 2019 American Thoracic Society (ATS) conference, held May 17–22 in Dallas, Texas. The PFF Patient registry, launched in 2016, is a comprehensive collection of patient…
Patients with idiopathic pulmonary fibrosis (IPF) produce a large amount of abnormal airway immune cells lacking an iron receptor that plays an important role in defending the lungs against pollutants and microbes, a study shows. The missing iron receptor is strongly correlated with poor clinical outcomes for patients, and…
An international group of experts and advocates in idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs) have joined to create the Open Source Imaging Consortium (OSIC), a not-for-profit effort to advance the diagnosis of these illnesses with the help of digital imaging and machine learning. According…
The first patient was dosed in a Phase 2b clinical trial investigating the safety and effectiveness of Respivant Biosciences’ inhalation therapy candidate RVT-1601 for idiopathic pulmonary fibrosis patients with persistent cough. Respivant Biosciences also has launched a new website — IPFcough.com — to increase awareness about the effects of cough…
An idiopathic pulmonary fibrosis (IPF) treatment candidate that mimics a tiny RNA molecule lowered the production of key profibrotic proteins and blocked fibrosis development in a mouse model of the disease. The data was presented recently at the 2019 American Thoracic Society (ATS) Conference in Dallas, in a poster titled “…
RaDaR, the catchy new name for the U.S. government-run Rare Diseases Registry Program, aims to help patient advocacy groups with limited resources build their own disease registries. The site was developed by the National Center for Advancing Translational Sciences (NCATS), a division of the National Institutes of…
Promedior‘s investigational therapy for idiopathic pulmonary fibrosis (IPF) — PRM-151 — continues to benefit patients after 76 weeks of treatment, slowing the decline in lung function and exercise capacity, while maintaining a similar safety profile as previous studies of PRM-151, an extension study shows. The results were…
Naftopidil treatment causes growth arrest of human lung fibroblasts and reduces fibrotic lesions in mice with idiopathic pulmonary fibrosis (IPF), a study shows. The findings of the study, “Naftopidil reduced the proliferation of lung fibroblasts and bleomycin‐induced lung fibrosis in mice,” were published in the Journal…
Get regular updates to your inbox.
